Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells

Area of Science:

• Vascular Biology
• Immunology
• Pharmacology

Background:

• Endothelial cells produce platelet-activating factor (PAF) in response to inflammatory stimuli like thrombin.
• PAF is implicated in inflammatory, immune processes, and coronary vasoconstriction.
• Nitric oxide (NO)-generating vasodilators, such as sodium nitroprusside (SNP) and SIN-1, relax blood vessels and inhibit platelet aggregation via soluble guanylate cyclase activation.

Purpose of the Study:

• To investigate the effect of NO-generating vasodilators on PAF synthesis in human umbilical vein endothelial cells (HUVEC).
• To elucidate the mechanism by which NO influences PAF production and related cellular processes.

Main Methods:

• HUVEC were treated with SNP and SIN-1.
• cGMP production and thrombin-induced PAF synthesis were measured.
• The activity of phospholipase A2 and acetyltransferase involved in PAF synthesis was assessed.
• The effect of 8-bromo-cGMP was evaluated.

Main Results:

• SNP and SIN-1 stimulated cGMP production and inhibited thrombin-induced PAF synthesis in HUVEC in a concentration-dependent manner.
• 8-bromo-cGMP mimicked the inhibitory effects of NO-generating vasodilators.
• NO-generating vasodilators dose-dependently inhibited the activation of phospholipase A2 and acetyltransferase in thrombin-stimulated HUVEC.
• These findings suggest NO endogenous action on vascular tone and intercellular adhesion.

Conclusions:

• Endogenous nitric oxide (NO) inhibits PAF production in endothelial cells, targeting key enzymes in the synthesis pathway.
• This mechanism highlights a novel action of nitrovasodilators, impacting vascular tone and inflammatory responses.
• PAF production in endothelial cells is a significant target for the pharmacological effects of nitrovasodilators.